Clinical trial
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to…
NCT00345839 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00345839 |
|---|---|
| Title | E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events |
| Official title | EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events |
| Acronym | EVOLVE |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Secondary Hyperparathyroidism, Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | Cinacalcet, Placebo |
| Enrollment | 3,883 |
| Start date | Aug 22, 2006 |
| Primary completion | Apr 10, 2012 |
| Completion | Apr 10, 2012 |
| First posted | Jun 29, 2006 |
| Last update posted | Nov 7, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: